{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:27:37Z","timestamp":1782358057760,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The prevalence of hypothalamic-pituitary-adrenal impairment (HPAI) in adults with Prader Willi Syndrome (PWS) remains unclear despite its clinical relevance. The aim of our study was to assess the prevalence of HPA axis impairment in adults with PWS based on the results of the high dose short synacthen test (HDSST), as well as to analyze the effects of hydrocortisone (HCT) therapy in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Thirty adult patients (14 men, 16 women, aged 18\u201328 years) with genetically confirmed PWS. Twenty-two patients (73.3%) had been adequately treated with human recombinant growth hormone (rhGH). Due to hypogonadotropic hypogonadism, all patients received hormone replacement therapy<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Physical examination included measuring height, weight and body fat percentage (using the electrical bioimpedance method). Based on HDSST results, patients were divided into two groups: with HPA axis impairment (cortisol &amp;lt; 500 nmol\/L at 30<jats:sup>th<\/jats:sup> minute), and AS (adrenal sufficiency; cortisol \u2265 500 nmol\/L at the 30<jats:sup>th<\/jats:sup> minute). Clinical symptoms of adrenal insufficiency (AI), body weight and body fat percentage were evaluated at baseline, after 6 and 12 months of follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen of the 30 patients (46.7%) showed a 30-min cortisol peak &amp;lt;500 nmol\/L, and were assigned to the HPAI group. Peak cortisol levels at 30\u2019 and 60\u2019 were significantly lower in the HPAI group compared to the Control one, respectively (<jats:italic>P<\/jats:italic>&amp;lt;0.001) Correlation analysis revealed that basal cortisol was positively correlated with cortisol levels at both 30\u2019 and 60\u2019 of the HDSST (r = 0.872, <jats:italic>P<\/jats:italic> &amp;lt; 0.001 and r = 0.829, <jats:italic>P<\/jats:italic> &amp;lt; 0.001, respectively). Fatigue, myalgia and muscle weakness occurred more often in the HPAI group than in the Control group (90.9% vs. 20%, <jats:italic>P<\/jats:italic>= 0.01, 90.9% vs. 0%, <jats:italic>P<\/jats:italic>=0.001, respectively). All symptomatic patients with HPAI received HCT treatment (10 mg\/day) in two divided doses. Fatigue, myalgiaand muscle weakness improved significantly after 12 months of HCT therapy (P&amp;lt;0.001). No adverse effects of HCT treatment were observed, such as weight gain, body fat percentage increase or metabolic abnormalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of our study suggest that the HPA axis should be routinely evaluated in adult patients with PWS. Short term, low-dose HCT treatment in symptomatic patients with HPAI is safe and can reduce symptoms of fatigue, myalgia and muscle weakness. However, the benefits and adverse effects of HCT treatment in this population require confirmation in prospective, placebo-controlled randomized clinical studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1517334","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:14:32Z","timestamp":1749010472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of hypothalamic-pituitary-adrenal axis impairment and effects of hydrocortisone treatment in adults with Prader-Willi syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Magdalena","family":"G\u00f3ralska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pokrzywa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sta\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Libura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Bednarczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0649","article-title":"Recommendations for the diagnosis and management of Prader-Willi syndrome","volume":"93","author":"Goldstone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.2013.79.issue-3","article-title":"Central adrenal insufficiency in young adults with Prader-Willi syndrome","volume":"79","author":"Grugni","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2018.0047","article-title":"Management of Prader-Willi Syndrome (PWS) in adults \u2014 what an endocrinologist needs to know","volume":"69","author":"Go\u0301ralska","year":"2018","journal-title":"Recommendations Polish Soc Endocrinol Polish Soc Paediatric Endocrinol Diabetology. Endokrynologia Polska"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2006)111[193:MIPS]2.0.CO;2","article-title":"Mortality in prader-willi syndrome","volume":"111","author":"Einfeld","year":"2006","journal-title":"Am J Ment Retard"},{"key":"B5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/jmg.38.11.792","article-title":"Population prevalence and estimated birth incidence and mortality rate for people with Prader \u2013 Willi syndrome in one UK Health Region","volume":"38","author":"Whittington","year":"2001","journal-title":"J Med Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ajmg.a.20371","article-title":"Prader-Willi syndrome: causes of death in an international series of 27 cases","volume":"124","author":"Schrander-Stumpel","year":"2004","journal-title":"Am J Med Genet Part A"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.6.0447","article-title":"Endocrine dysfunction in Prader\u2013Willi syndrome: a review with special reference to GH","volume":"22","author":"Burman","year":"2001","journal-title":"Endocrine Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0555-3","article-title":"Pituitary height and neuroradiological alterations in patients with PraderLabhart-Willi syndrome","volume":"167","author":"Iughetti","year":"2008","journal-title":"Eur J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/ajmg.a.v124a:2","article-title":"Unexpected death and critical illness in Prader \u2013 Willi syndrome: report of ten individuals","author":"Stevenson","year":"2004","journal-title":"Am J Med Genet Part A"},{"key":"B10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2265.2010.03853.x","article-title":"Adrenal function and mortality in children and adolescents with Prader-Willi syndrome attending a single centre from 1991-2009","volume":"73","author":"Connell","year":"2010","journal-title":"Clin Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1210\/jc.2007-2294","article-title":"High prevalence of central adrenal insufuciency in patients with Prader-Willi syndrome","volume":"93","author":"de Lind van Wijngaarden","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0487","article-title":"No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test","volume":"31","author":"Obrynba","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.5.4831","article-title":"Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease","volume":"83","author":"Mayenknecht","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0782","article-title":"Normal cortisol response to high dose synachten and insulin tolerance test in children and adults with Prader-Willi syndrome","volume":"96","author":"Farholt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13492-7","article-title":"Adrenal insufficiency","volume":"361","author":"Arlt","year":"2003","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.03.012","article-title":"New reference values for body composition by bioelectrical impedancje analysis in the general population: results from the UK Biobank","volume":"15","author":"Franssen","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-017-0293-2","article-title":"Adiponectin\/resistin interplay in serum and in adipose tissue of obese and normal-weight individuals","volume":"9","author":"Jonas","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"W. Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7735","article-title":"Hypothalamo \u2013 pituitary \u2013 adrenal axis function in chronic fatigue syndrome, and the effents af low-dose hydrocortisone therapy","volume":"86","author":"Cleare","year":"2001","journal-title":"JCEM"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4158\/EP171861.OR","article-title":"Diagnostic accuracy of basal cortisol level to predict adrenal insufficiency in cosyntropin testing Results from an observational cohort study with 804 patients","volume":"23","author":"Struja","year":"2017","journal-title":"EndocrPract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0710","article-title":"Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis","volume":"93","author":"Kazlauskaite","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","article-title":"The assessment of the hypothalamicpituitary-adrenal axis in pituitary disease: are there short cuts","volume":"26","author":"Dickstein","year":"2003","journal-title":"J Endocrinological Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.9.5947","article-title":"Optimizing the diagnostic criteria for standard (250-microg) and low dose (1-microg) adrenocorticotropin tests in the assessment of adrenal function","volume":"84","author":"Zarkovi\u0107","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1700","article-title":"ACTH stimulation tests for the diagnosis of adrenal insufficiency: Systematic review and meta-analysis","volume":"101","author":"Ospina","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38713","article-title":"Delayed peak response of cortisol to insulin tolerance test in patients with Prader-Willi syndrome","volume":"176","author":"Oto","year":"2018","journal-title":"Am J Med Genet A."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0647","article-title":"Normal cortisol response on low-dose synacthen (1 microg) test in children with Prader Willi syn-drome","volume":"95","author":"Nyunt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105(7","DOI":"10.1210\/clinem\/dgaa168","article-title":"Central adrenal insufficiency is rare in adults with prader-willi syndrome","volume":"1","author":"Rosenberg","year":"2020","journal-title":"J Clin Endocrinol Metab Jul"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.12.1061","article-title":"Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial","volume":"280","author":"McKenzie","year":"1998","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2018.11.014","article-title":"Changes in health- related outcomes in youth with obesity in response to a home-based parent-led physical activity program","volume":"65","author":"Rubin","year":"2019","journal-title":"J Adolesc Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cen.2019.90.issue-5","article-title":"Physical exercise and Prader-Willi syndrome: A systematic review","volume":"90","author":"Morales","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000023533","article-title":"Is there growth hormone deficiency in prader-willi Syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader-Willi syndrome","author":"Eiholzer","year":"2000","journal-title":"Horm Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15091","article-title":"Adrenal insufficiency\u202fdetection in patients with immunoglobulin A nephropathy, lupus\u202fnephritis, and transplant recipients qualified for glucocorticoid withdrawal","volume":"129","author":"Pokrzywa","year":"2019","journal-title":"Pol Arch Intern Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1517334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:14:32Z","timestamp":1749010472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1517334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":34,"alternative-id":["10.3389\/fendo.2025.1517334"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1517334","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1517334"}}